Gan & Lee Pharmaceuticals.

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 12/01/2026			5-day change	1st Jan Change
69.88 ^CNY	-1.58%		+2.66%	+2.66%

01-02	Gan & Lee Pharmaceuticals Removes CFO, Appoints Acting CFO	MT
12-29	Lupin Limited Enters into License, Supply and Distribution Agreement with Gan & Lee Pharmaceuticals for Novel GLP-1 Receptor Agonist, Bofanglutide	CI

Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2025

Published on 04/24/2025 at 01:47 pm BST

S&P Capital IQ

Gan & Lee Pharmaceuticals.

-1.58%

Gan & Lee Pharmaceuticals. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported sales was CNY 984.87 million compared to CNY 560.33 million a year ago.

Revenue was CNY 984.87 million compared to CNY 560.33 million a year ago. Net income was CNY 311.92 million compared to CNY 96 million a year ago. Basic earnings per share from continuing operations was CNY 0.53 compared to CNY 0.16 a year ago.

Diluted earnings per share from continuing operations was CNY 0.53 compared to CNY 0.16 a year ago.

Latest news about Gan & Lee Pharmaceuticals.

01-02	Gan & Lee Pharmaceuticals Removes CFO, Appoints Acting CFO	MT
12-29	Lupin Limited Enters into License, Supply and Distribution Agreement with Gan & Lee Pharmaceuticals for Novel GLP-1 Receptor Agonist, Bofanglutide	CI
12-09	Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug	MT
11-18	Gan & Lee Pharmaceuticals Europe GmbH Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Recommends the Approval of Insulin Glargine Injection	CI
30/10/25	Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
17/10/25	Gan & Lee Pharmaceuticals Appoints Dr. Ting Jia as Chief Medical Officer	CI
29/09/25	Gan & Lee Pharmaceuticals Signs National "Technology Transfer and Supply Agreement" in Brazil to Accelerate Local Insulin Manufacturing	CI
23/09/25	Gan & Lee Pharmaceuticals signs framework agreement	RE
07/09/25	Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	CI
02/09/25	Gan & Lee Pharmaceuticals.'s Equity Buyback announced on September 6, 2024, has expired with 3,540,021 shares, representing 0.6% for CNY 150.07 million	CI
08/08/25	Gan & Lee Pharmaceuticals' lH1 Profit Jumps 103%, Revenue Rises 57%	MT
07/08/25	Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
07/08/25	Gan & Lee Pharmaceuticals' H1 net profit up 102.0% Y/Y	RE
09/07/25	Gan & Lee Pharmaceuticals sees H1 net profit up 100.7-114.1% Y/Y	RE
08/07/25	Gan & Lee Pharmaceuticals' Insulin Aspart Receives Approval in Argentina	CI
21/06/25	Gan & Lee Pharmaceuticals Presents Multiple Results in Novel Diabetes Therapies At the American Diabetes Association's 85Th Scientific Sessions	CI
19/05/25	Gan & Lee Pharmaceuticals Completes First Patient Dosing in GZR102 Trial	MT
25/04/25	Gan & Lee Pharmaceuticals' 2024 Profit Jumps 81%, Operating Income Rises 17%; Shares Jump 10%	MT
25/04/25	Gan & Lee Pharmaceuticals' Q1 Profit Surged 225%, Operating Income Jumps 76%; Shares Jump 10%	MT
24/04/25	Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
23/04/25	Gan & Lee Pharmaceuticals Gets Nod to Trial Diabetes Drug	MT
02/04/25	Gan & Lee Pharma's Insulin Glargine Injection Gets Registration Nod in Pakistan	MT
01/04/25	Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	CI
11/03/25	Gan & Lee Pharmaceuticals Doses First Subject for Phase II Clinical Trial of Bovanglutide Injection	MT
10/03/25	Gan & Lee Pharmaceuticals Announces First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide Injection for Overweight or Obesity	CI

Chart Gan & Lee Pharmaceuticals.

Duration

Period

603087: Dynamic Chart

Company Profile

Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.

Employees

5,245

Sector

Pharmaceuticals

Calendar

04-22 - Q4 2025 Earnings Release

More about the company